Nanosphere (NSPH) Gets De Novo Petition from FDA to Market Gram-Positive BC-GP
Tweet Send to a FriendGet Alerts NSPH Hot Sheet
Trade NSPH Now!
Nanosphere, Inc. (Nasdaq: NSPH), reports the U.S. Food and Drug Administration has granted a de novo petition permitting marketing of its Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) on the automated sample-to-result Verigene System.
The BC-GP test notably expands Nanosphere's infectious disease test capabilities to include fast detection of bacteria that can cause deadly bloodstream infections, an increasingly recognized health threat.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The BC-GP test notably expands Nanosphere's infectious disease test capabilities to include fast detection of bacteria that can cause deadly bloodstream infections, an increasingly recognized health threat.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Abbott (ABT) Receives CE Mark for XIENCE Coronary Stent System
- AcelRx Pharma (ACRX) Stock Higher; Sufentanil NanoTab Study Meets Primary Endpoint
- Hologic (HOLX) Announces FDA Approval of C-View 2D Imaging for or Breast Cancer Screening
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
